In one study, exogenous histidine administration resulted in a decrease in the expression of tumor markers associated with glycolysis (GLUT1 and HK2), inflammation (STAT3), angiogenesis (VEGFB and VEGFC), and stem cells (CD133) [40]. The gene discussed is SLC2A1; the disease is neoplasm.